Description
Daclahep (Daclatasvir) 60mg Tablets Online
Daclahep (Daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Daclatasvir is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis. Daclatasvir is given together with another drug called Sovaldi (sofosbuvir).
Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 3 infection. Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication.
Daclatasvir, in combination with sofosbuvir, is an effective and recommended alternative for the treatment of HCV in patients with genotype 2, in either treatment-naive patients or peginterferon/ribavirin treatment-experienced patients (without cirrhosis or with compensated cirrhosis). Daclatasvir, in combination with sofosbuvir (with or without ribavirin), is also an effective and recommended regimen in patients with decompensated cirrhosis and, in combination with sofosbuvir and ribavirin, in liver transplant patients with or without compensated or decompensated cirrhosis.
Daclatasvir comes as a tablet to take by mouth. It is usually taken with or without food once a day. Daclatasvir must be taken in combination with sofosbuvir, usually for 12 weeks. Take daclatasvir at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take daclatasvir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
